<DOC>
	<DOCNO>NCT01077505</DOCNO>
	<brief_summary>This study open-label study evaluate effect albiglutide pharmacokinetics pharmacodynamics standard oral contraceptive regimen ( Brevicon ) . The primary objective study demonstrate lack effect albiglutide dose pharmacokinetics norethindrone ethinyl estradiol healthy female subject .</brief_summary>
	<brief_title>An Evaluation Pharmacokinetics Oral Contraceptive ( Brevicon ) When Co-administered With Albiglutide .</brief_title>
	<detailed_description>This study open-label study least one center evaluate effect albiglutide administration pharmacokinetics pharmacodynamics standard oral contraceptive regimen ( Brevicon ) . The primary objective study demonstrate lack effect albiglutide dose pharmacokinetics norethindrone ethinyl estradiol healthy female subject .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>rGLP-1 protein</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<mesh_term>Mestranol</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Norethindrone acetate , ethinyl estradiol , ferrous fumarate drug combination</mesh_term>
	<mesh_term>Norinyl</mesh_term>
	<mesh_term>Norethindrone</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>Healthy female subject , define individual free clinically significant illness disease determine medical history , physical examination , clinical laboratory test , 12lead ECG ; Women childbearing potential must use protocoldefined contraceptive method ; BMI 19 30 kg/m2 body weight ≥50 kg ( 110 lb ) &lt; 114 kg ( &lt; 250 lb ) ; Aspartate aminotransferase ( AST ) , ALT , alkaline phosphatase , bilirubin &lt; /=1.5 × ULN ; Any clinically relevant abnormality identify screen medical assessment , laboratory examination , ECG ; Blood pressure ≥140/90 mm Hg heart rate &gt; 100 beats/minute Screening ; Corrected QT ( QTc ) interval &gt; 450 msec ( per ECG machine interpretation ) ; Pregnant nursing female ; A positive prestudy hepatitis B surface antigen , positive hepatitis C antibody , HIV result within 3 month Screening ; Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) ; Smoking use nicotine product , include smoke cessation patch contain amount nicotine within 6 month Screening ; Women childbearing potential unwilling unable use appropriate method contraception ; Subjects participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives , twice duration biological effect investigational product ( whichever longer ) ; History substance abuse within past year determine investigator ; History alcohol abuse define average weekly intake &gt; 7 drink ; Positive urine drug screen Screening predose Runin Period Day 1 Periods 1 2 ; Use prescription nonprescription drug , vitamin , dietary/herbal supplement include St. John 's Wort , nonsteroidal antiinflammatory medication , aspirin within 14 day 5 halflives , whichever long prior first dose investigational product ; Willing refrain consume grapefruit cranberry product ( juice , fruit , nutritional supplement ) time participation study ; Donation blood excess 500 mL within 56 day prior dose intention donate month complete study ; History thyroid dysfunction abnormal ( i.e. , outside normal reference range ) thyroid function test assess thyroid stimulate hormone ( TSH ) Screening ; History drug allergy allergy , , opinion responsible study physician , contradict subject 's participation ; History condition would contraindicate OC administration ( include hypertension , stroke , ischemic heart disease , venous thromboembolism , carcinoma breast , etc . ) ; History type 1 2 diabetes mellitus ; History migraine age &gt; 35 year focal symptom associate migraine ; Any condition would affect drug transit time absorption ( e.g. , gastrointestinal bypass surgery , partial total gastrectomy , small bowel resection , chronic diarrhea , vagotomy , chronic gastroesophageal reflux disease , malabsorption , colostomy , Crohn 's disease , ulcerative colitis , celiac sprue ) ; Previous current receipt exenatide GLP 1 agonist ;</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>pharmacokinetics</keyword>
	<keyword>GSK716155</keyword>
	<keyword>Brevicon</keyword>
	<keyword>albiglutide</keyword>
	<keyword>healthy female volunteer</keyword>
	<keyword>oral contraceptive</keyword>
</DOC>